Stockscreener 앱 받기
7.45
9.40%
0.64
시장 영업 전:
7.51
0.06
+0.81%
전일 마감가:
$6.81
열려 있는:
$6.95
하루 거래량:
1.76M
Relative Volume:
1.42
시가총액:
$1.10B
수익:
$177.28M
순이익/손실:
$-195.24M
주가수익비율:
-5.5597
EPS:
-1.34
순현금흐름:
$-114.54M
1주 성능:
+22.73%
1개월 성능:
+16.59%
6개월 성능:
+84.41%
1년 성능:
+80.83%
1일 변동 폭
$6.95
$7.50
1주일 범위
$6.34
$7.50
52주 변동 폭
$2.28
$7.50
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
명칭
Adaptive Biotechnologies Corp
전화
206-659-0067
주소
1165 EASTLAKE AVE E, SEATTLE, WA
ADPT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
7.45 | 1.10B | 177.28M | -195.24M | -114.54M | -1.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-12-21 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-08-25 | 개시 | Credit Suisse | Underperform |
| 2022-06-03 | 개시 | Piper Sandler | Neutral |
| 2022-02-16 | 재확인 | BTIG Research | Buy |
| 2022-02-16 | 재확인 | BofA Securities | Buy |
| 2022-02-16 | 재확인 | Goldman | Neutral |
| 2022-02-16 | 재확인 | JP Morgan | Overweight |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-03-03 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-10-08 | 재개 | BTIG Research | Buy |
| 2020-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-06-03 | 개시 | Goldman | Buy |
| 2019-07-23 | 개시 | BTIG Research | Buy |
| 2019-07-22 | 개시 | BofA/Merrill | Buy |
| 2019-07-22 | 개시 | Cowen | Outperform |
| 2019-07-22 | 개시 | Goldman | Neutral |
| 2019-07-22 | 개시 | Guggenheim | Buy |
| 2019-07-22 | 개시 | William Blair | Outperform |
모두보기
Adaptive Biotechnologies Corp 주식(ADPT)의 최신 뉴스
Adaptive Biotechnologies stock hits 52-week high at $7.47 - Investing.com India
Adaptive Biotechnologies Corp (NASDAQ: ADPT) Drops -1.59 Percent In Recent Trading, What Questions Do You Have? – Stocks Register - Stocks Register
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Sold by JPMorgan Chase & Co. - Defense World
Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Adaptive Biotechnologies (ADPT) Soars 18.0%: Is Further Upside Left in the Stock? - MSN
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Up 17.6%Time to Buy? - MarketBeat
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year - Benzinga
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Down 6.5%What's Next? - MarketBeat
Adaptive Biotechnologies and NeoGenomics partner to expand access to disease monitoring for blood cancer patients - Seeking Alpha
Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients - Yahoo Finance
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Acquired by Barclays PLC - MarketBeat
Cathie Wood's Ark Invest Trims Palantir Again As Peter Thiel Co-Founded Firm's Stock Tumbles Nearly 15% In 2025 - Benzinga
Adaptive Biotechnologies: 1Q Earnings Snapshot -May 12, 2020 at 04:27 pm EDT - Marketscreener.com
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics Which Laid Off Over A Quarter Of Its Workforce - Benzinga
Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025 - Yahoo Finance
Adaptive Biotechnologies (NASDAQ:ADPT) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Adaptive Biotechnologies stock hits 52-week high at $7.08 By Investing.com - Investing.com Australia
Adaptive Biotechnologies (NASDAQ:ADPT) Hits New 12-Month HighStill a Buy? - MarketBeat
Adaptive Biotechnologies stock hits 52-week high at $7.08 - Investing.com
Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Yahoo Finance
Adaptive Biotechnologies (NASDAQ:ADPT) Trading 7.3% HigherHere's Why - MarketBeat
Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Geode Capital Management LLC Sells 20,450 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Sees Significant Drop in Short Interest - MarketBeat
Seattle InnoAdaptive's royalty financing I Changes at Tanium - The Business Journals
Barclays PLC Has $1.18 Million Stake in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Stock Holdings Lifted by Barclays PLC - MarketBeat
Adaptive Biotechnologies Corporation Provides MRD Business Revenue Guidance for the Full Year 2024 - Marketscreener.com
State Street Corp Acquires 48,885 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Sold by Jane Street Group LLC - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) vs. Moderna (NASDAQ:MRNA) Financial Comparison - Defense World
BTIG Research Raises Adaptive Biotechnologies (NASDAQ:ADPT) Price Target to $9.00 - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Down 6.6%What's Next? - MarketBeat
Are Medical Stocks Lagging BellRing Brands (BRBR) This Year? - Yahoo Finance
Charles Schwab Investment Management Inc. Purchases 10,262 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
ARK Invest Shakes Up Portfolios! Major Tech Sell-Off and Biotech Bets! - Jomfruland.net
Top 3 Health Care Stocks That May Collapse This Quarter - Benzinga
ADPT stock touches 52-week high at $6.71 amid robust gains By Investing.com - Investing.com South Africa
ADPT stock touches 52-week high at $6.71 amid robust gains - Investing.com
Jacobs Levy Equity Management Inc. Makes New $736,000 Investment in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Point72 Asset Management L.P. Makes New $2.54 Million Investment in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Pier Capital LLC Grows Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions - Yahoo Finance
ADPT (Adaptive Biotechnologies) 10-Year Sortino Ratio : N/A (As of Dec. 06, 2024) - GuruFocus.com
ADPT (Adaptive Biotechnologies) 1-Year Sortino Ratio : 1.18 (As of Dec. 06, 2024) - GuruFocus.com
ADPT (Adaptive Biotechnologies) Interest Coverage : 0 (At Loss) (As of Sep. 2024) - GuruFocus.com
Adaptive Biotechnologies Corp (ADPT) With A Potential Upside Of More Than -193.16% - Stocks Register
Adaptive Biotechnologies (STU:1HM) Interest Coverage : 0 (At Loss) (As of Sep. 2024) - GuruFocus.com
Matrix Capital Management Company LP Sells 10,922,590 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Adaptive Biotechnologies (FRA:1HM) Earnings Yield (Joel Gre - GuruFocus.com
Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting - Yahoo Finance
Adaptive Biotechnologies Corp (ADPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):